Chronic paroxysmal hemicrania, hemicrania continua and SUNCT: the fate of the three first described cases by Ottar Sjaastad
Introduction
Chronic paroxysmal hemicrania (CPH) was first described
in 1974 [1, 2], and SUNCT syndrome in 1977 [3, 4], where-
as hemicrania continua was described in 1984 [5]. The first
CPH patient was observed 13 years prior to the description.
The total time of observation for the first patient with each
of these headaches has been considerable (Table 1).
Contact has been kept with these patients, also in
recent years, although generally on a more sporadic and
distant basis. The development of their headaches is,
therefore, generally known. Two of these patients have
died (SUNCT and hemicrania continua, see Table 1),
while the CPH patient is still alive at 89 years of age.
It is time to try to sum up what lessons may be learned
from these long-lasting observations.
Chronic paroxysmal hemicrania (CPH)
The CPH patient was a female, born in 1917. Attacks
started at 35, just after delivery (Table 1). We were con-
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Abstract The first patient with
chronic paroxysmal hemicrania has
been followed for 45 years, and for
33 years with indomethacin treat-
ment. The headache became less
severe with time; there was no
indomethacin tachyphylaxis. The
first patient with SUNCT was fol-
lowed for 28 years, until his demise
at 89. Pain became worse with
time. No adequate therapy was
found. The first patient with
Hemicrania continua was followed
for 19 years, until her demise at 81.
She was treated with indomethacin
during the whole observation time.
There was no tachyphylaxis. Both
patients treated with indomethacin
developed gastric ulcer. And both
had gastric surgery. Indomethacin
therapy may be a life-long affair.
The risk of gastric complications
may be substantial.
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sulted in 1961 – at 44. There were up to ≥20 attacks per
day of about 20 min duration at the peak of complaint.
The complaints fluctuated markedly, but there was never
a headache-free day. Attacks were always right-sided,
and they were accompanied by local, autonomic phe-
nomena (lacrimation etc.). She had herself, years prior to
the first consultation with us, found that acetylsalicylic
acid was of some use, and she took up to 6–8 g/day.
During the period of acetylsalicylic acid consumption,
she developed a gastric ulcer along the lesser curvature
several times, and a Billroth II operation was carried out
in 1968 for this reason.
It is striking how many surgical operations she has
undergone. She was particularly interested in having
assessed whether there were any organs on the right
(symptomatic) side that ought to be dealt with, surgical-
ly. Molars in the upper jaw, symptomatic side, were
removed. A benign tumour was removed from the right
kidney. An artificial hip joint was implanted on the
symptomatic side. And she, finally, had the gallbladder
removed. But also midline organs were removed: a hys-
terectomy was carried out. And even organs on the non-
symptomatic side were removed: bilateral ovariectomy
was carried out, in a separate operation. Moreover, there
is a renal cyst (hydronephrosis?; present for >40 years?)
on the non-symptomatic side, for which surgery has been
considered.
It is also worthy of note that originally minor pto-
sis/miosis seemed to be present, on the symptomatic side.
Horner’s syndrome was, therefore, suspected (also in
other early patients). This suspicion was later annulled. In
a collaboration with Professor Stephen Smith in London,
a world authority on pupillometry, it was demonstrated
that there is no Horner’s syndrome in CPH (patient no. 1
was included in the study [6]).
The latter study should be noted, as there are many
cases of a so-called Horner’s syndrome in unilateral
headaches reported in the literature, without even an
attempt to verify it. All such communications should be
regarded with due suspicion.
Recent years
She has been medicated with indomethacin since 1973 – a
period of 33 years. Indomethacin immediately removed
her pain attacks entirely and permanently, provided the
dosage was correct. She became a master in titrating the
dosage according to the varying extent of her complaints.
The indomethacin dosage usually varied between 25 and
50 mg/day; a 75 mg dosage was necessary to keep the pain
at bay during the worst periods. During troughs, 25 mg
every second day might do.
In recent years, she has only used indomethacin on
attack days. When trying to adjust the dosage at the onset
of an exacerbation, she could have more than just a hunch
as regards the attack frequency. From such experiences,
she has the clear impression that an improvement has
taken place over the years, as regards the temporal pattern:
the attacks became shorter, and there was a longer interval
between attacks; there were rarely more than 1–2 attacks
per day, and in recent months there have been up to three
weeks between attacks. The attacks have become less
severe. Nevertheless, attacks may still wake her up at
night. She has not had a single “big attack” for more than
a year and a half.
Attacks as such are still accompanied by lacrimation,
conjunctival injection and rhinorrhoea. During all these
years of pain freedom, she never noticed episodes of only
autonomic features, i.e., solitary lacrimation, rhinorrhoea
or conjunctival injection. We did not check for forehead
sweating and arrhythmia on a subclinical scale during
recent years. The pain was located in the same area, cen-
Table 1 CPH, SUNCT, HC. Gross development
CPH SUNCT Hemicrania continua
Birth 1917* 1916** 1920**
Onset headache 1952* 1946** 1945**
Age, onset 35* 30** 25**
First consultation with us, age 44* 61** 62**
Indomethacin from, age 56* –** 62**
Present age*/demise**, age 89* 89** 81**
Observation time, years 45* 28** 19**
Total duration of headache, years 54* ≤60** 56**
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tring on the eye, but it was also felt in the forehead, tem-
poral area, cheek and throat and down to the breast, all on
the symptomatic side.
She has had three coronary infarctions in recent years.
Blood pressure was 115/55. She presently suffers from
heart disease and dyspepsia, in spite of taking drugs to
reduce acid production. Dyspepsia is in all likelihood sec-
ondary to indomethacin medication.
She is nevertheless absolutely clear on two points:
indomethacin has “saved her life”, and, there would be
“no way” that she at any time would have relinquished
indomethacin. Indomethacin has retained its effect after
33 years. There has been no tachyphylaxis. The intensity
and duration of attacks in this patient have been reduced
with time, and the interval between attacks has been dras-
tically changed. But the disorder still persists after 54
years (Table 1). Dyspepsia and gastric ulcer have followed
in the wake of acetylsalicylic acid and indomethacin med-
ication. In spite of these setbacks, the medication could be
continued until now.
SUNCT syndrome
The first patient (i.e., no. I [3]) was a male, born in 1916
(Table 1). Right-sided ocular/periocular pain in 1–3-
week long, biannual bouts started at around 30 years of
age. In the early phase, there was usually a continuous,
low-grade discomfort, with occasional minor exacerba-
tion during the bouts. A decade or more later there was
a transformation from the more continuous pain to
paroxysms. This development seemed to have reached a
plateau at the age of 58. There were then periods with
attacks 6–9 months per year. The attack frequency
ranged from 5 to 30 per hour, and the mean duration was
15 s (range 10–60 s). During the worst periods, the pain
was fairly intense, with nocturnal awakenings; other-
wise, the pain seemed to be moderately intense. There
was no restlessness during attacks. Attacks were accom-
panied by conjunctival injection, lacrimation and rhin-
orrhoea (and sub-clinical forehead sweating), all on the
symptomatic side. Moreover, corneal indentation pulse
(CIP) amplitudes and intraocular pressure increased
markedly on the symptomatic side during attacks [8]
(Table 2). There was also a clear asymmetry of forehead
sweating during attacks (most marked on symptomatic
side) [9]. Attacks could be precipitated by blowing the
nose, extension and rotation of the head, brushing teeth,
chewing (in particular sour apples) etc. No drugs,
including those for trigeminal neuralgia, were found to
be of any use.
The last years
General health
At 75, cancer of the prostate was detected. Its growth
seems to have been slowed down by medication
(Zoladux), but at 88, a spreading to the skeleton was veri-
fied, and – 4 months later – local pain started. At 87, a
coronary by-pass operation was carried out. He recovered
quickly from that. His demise at 89 years of age was due
to an acute heart attack.
The headache
He always accepted, willingly, new investigations and new
trials, his attitude being: this will probably not help me,
but – maybe – those that come after me.
Various drugs were tried, none of them being effec-
tive [7]. At 75 years of age, he had amalgam totally
removed from his teeth, and, simultaneously, two upper
jaw molars (root-filled ones) were removed. He appar-
ently felt better for the next two years, with more mod-
erate pain and longer pain-free intervals. Thereafter, the
pain attacks recurred with the same intensity as before.
The last molar on the symptomatic side was removed at
87; and again there seemed to be a transitory improve-
ment. The precipitation mechanisms in recent years
were mainly neck movements, and the “beginning of
chewing”. All in all, during the last 8–9 years, the
attacks were severe, possibly even more so than previ-
ously. And “they were of longer duration than before”.
Carbamazepine was continued until the end, in spite of
the tendency to worsening of attacks. Attacks thus per-
sisted until the end. There was thus no trend towards a
late-stage amelioration. On the contrary, there seems to
have been a deterioration. The case history probably
Table 2 Ocular variables in SUNCT and other unilateral headaches




CPH (n=7) 63 28
Cluster headache (n=18) 48 12
Hemicrania continua (n=2) c No changes
aCorneal indentation pulse amplitudes, see Refs [8, 10]
bPresent patient: no. of solitary observations: 7
cA questionable increase on the symptomatic side in one of the
patients
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lasted close to 60 years and the prospective study 28
years (Table 1).
Hemicrania continua (HC)
The first patient (no. I [5]) was born in 1920. The strict-
ly left-sided headache apparently started in 1945, at 25
years of age (Table 1). When first seen by us in 1983,
she was 62 years old. The headache was continuous
from the outset, and it was localised in the oculo-frontal
and temporal areas. It was moderately intense, and there
were only moderate fluctuations in the intensity. There
were occasional, 1–3-s long jabs in the painful area. But
there were no visible, localised, autonomic phenomena;
the ocular variables showed no clear-cut abnormalities
(Table 2).
For more than 30 years, she used up to 6 g acetylsali-
cylic acid per day, and that had taken away the top of the
pain. Indomethacin was instituted in 1983 and took away
the pain after 4–6 h, the effect being both complete and
durable. The correct dosage seemed to be 75 mg; 50 mg
did not quite suffice.
The last years
There had been mild, periodic, gastric distress through the
years, on both acetylsalicylic acid and indomethacin med-
ication. During a cold-season, durable stay in one of the
southern European islands, at 66, she fainted in the bath-
room during the night, due to a massive bleeding from a
2.5–3 cm wide ventricular ulcer. She was operated upon
immediately to stop the bleeding (on a close to vital indi-
cation). It is worth mentioning that this happened the last
night before a friend in the same flat was going to leave
her alone.
The gastric distress, nevertheless, continued and later
increased; it was only partially counteracted by cimeti-
dine. The risk of continued indomethacin medication
under these circumstances was carefully explained to
her, but a certain stubbornness came to the fore: “if any-
one dares to try to take away the indomethacin…” She
was the one who had these pains and knew how they
affected her. No one had the authority to give her
absolute instructions. We felt that there were no means
by which we could hinder her. The H2 receptor antago-
nist, cimetidine, was replaced by omeprazol (Losec), 20
mg/day, as a safeguard, and gastroscopy was – according
to plan – to be carried out every 6 months. As a conse-
quence of the not quite so regular, but nevertheless mul-
tiple gastroscopies, a gastric ulcer was detected six years
later; later a fibrin-covered ulcer was detected, and still
later, diffuse gastritis, twice.
Because of these findings, a couple of times she
agreed to reduce the indomethacin dosage (25 mg 1–2
times/day) and to live with a certain pain level
(40%–60%). But, alas, she was back again on the regular
dosage rather quickly. She had a short-lasting episode of
transient global amnesia at 65.
During the period from 1995, at 75, until her demise in
2001, at 81, we mostly had indirect contact with her. The
development from 1995 was as follows: the pain freedom
on 75 mg indomethacin continued unabridged. There was
no tachyphylaxis after 19 years of indomethacin usage.
She acquired (a) diffuse body pains (rheumatological
expertise examination gave no indications for rheumatoid
arthritis); (b) pyelonephritis (ESR:50 mm); (c) cancer
cutis (basal cell carcinoma, left temporal region); (d)
osteoporosis, with compression fracture at Th 12; (e) left-
sided, marked hydronephrosis; (f) chronic, obstructive
bronchitis and, finally (g) a low-grade, non-Hodgkin’s
lymphoma with abdominal tumour and bone marrow infil-
tration. There was reduced general health condition, peri-
odic fever (39°C) and anaemia (haemoglobin: 8.5 g/dl).
During this last stage, she also had a left lower extremity
vein thrombosis and was treated with warfarin (at 80). A
cerebral CT from the last years was normal; X-ray of the
cervical spine demonstrated uncovertebral arthrosis C5–7.
Her physician had been deeply concerned about her
NSAIDs usage – and cancelled it. Not long after, another
prescription indicated that she – again – was on
indomethacin, 50 mg/day. In other words, she used
indomethacin to the end, although (possibly!) in a slight-
ly reduced dosage. The headache was, as previously,
always left-sided, and it had the same characteristics – and
intensity – as before.
Comments
SUNCT continued its relentless course for close to 60
years and grossly kept its characteristics: the recurrent,
long-term pattern was still present. The severity of the dis-
order tended to increase with age, both with regard to pain
intensity, attack duration and frequency of attacks. No
drugs of any use were found. It is worth noticing that the
continuous course that prevailed during the bouts in the
first decade or so never showed up again. This initial, tem-
poral pattern distinguishes it from trigeminal neuralgia,
which some clinicians still think of as a differential diag-
nostic alternative.
The following inferences can be made at the present time:
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The marked increase in intraocular pressure and CIP
amplitudes in this SUNCT patient (Table 2) could only be
compared with cluster headache at the time; the difference
as for both variables is a major one. In all probability, this
indicates a difference in the pathogenesis of the two
headaches. Later, we obtained the results of the corre-
sponding studies in CPH (Table 2).
The difference between CPH and cluster headache is
sizeable, but the differences between CPH and SUNCT
are as marked for both variables. SUNCT, therefore,
seems to be in a group of its own [8].
The sweating pattern in SUNCT syndrome seems most
similar to that in CPH [9].
In HC [11] there were no definite abnormalities, as
regards the ocular variables (Table 2); forehead sweat
variables were also within the normal range [11].
HC lasted 56 years, and there were no signs of ame-
lioration. One may speculate that the gravely reduced gen-
eral health condition and the fever may have augmented
the headache complaints during her last years.
In the CPH patient, with a case history of 54 years, there
was, on the other hand, a clear tendency for the attacks to
become more moderate. The efficacy of indomethacin was
kept up both in CPH (33 years treatment) and in HC (19
years treatment) without any signs of tachyphylaxis.
Both patients with long-lasting indomethacin treat-
ment reached an old age in spite of the complication risk.
Their ages, 81 and 89 respectively, are at, respectively
well above the mean lifespan in Norway at this time. And
they have had a decent life in spite of the complications
and constant risk of complications.
The potentially harmful effects of long-term
indomethacin therapy make it imperative, not only in
those with intermittent symptoms, but also in those with
considerable fluctuation, to try to reduce/discontinue
indomethacin at intervals. The lowest effective dosage
should at all times be titrated.
An indomethacin test is a must in the diagnostic
process in both CPH and HC. This is the foundation of the
diagnosis, and it also represents the ethical basis for con-
tinued indomethacin therapy. To begin indomethacin ther-
apy, which in principle may be a lifelong treatment, is a
serious matter. The risk of upper gastro-intestinal tract
irritation/lesion seems in the long run to be considerable,
as seen in both the present patients. The routine gas-
troscopy practice that we introduced in one of our patients
represents a heavy load on the health system and may still
not be an adequate safeguard. Although CPH and HC are
two separate disorders, the problems connected with long-
term indomethacin therapy create a common complex of
problems. With long-term therapy, which in many cases
certainly will be necessary at this stage of development, a
strategy rendering the highest possible protection to the
gastric mucosa should be followed.
The story, in particular that of the HC patient, brings
up ethical considerations. Should indomethacin at one
stage have been forbidden? The fact is that the HC patient
could have expired during the one-time bleeding episode.
From the patients’ point of view, the matter appeared
quite differently. They were “in command of their own
lives” and wanted no interference with the drug consump-
tion. The conflict of interest was obvious and major.
Besides prescriptions, they wanted one thing from us: pro-
tect us from the gastro-intestinal complications as well as
you can, and we will take care of the rest – including the
dosage level.
These patients were craving the drug, almost like drug
addicts. They even warned us: the HC patient would do
“drastic things” if not given access to the drug; the CPH
patient time and again emphasised that the biggest river in
Norway ran close to her home.
We reasoned this way: one cannot send the police to the
domestic sphere to enforce a ban on indomethacin usage.
To enforce the ban by allotting “police authority” to a fam-
ily member would also create non-sustainable conditions
within the family. A patient who is up and about will be able
to provide the drug – and to hide it. The only way, as we
saw it, would be to convince the patient of the real and great
danger – the Damocles sword, so to speak. The patients
understood – and accepted – the danger. They were pre-
pared to meet whatever dangers there were, even exitus, if
only they could have a decent life – as long as they lived.
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